Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected naïve Patients Using Test and Treat Stategy Rapid-initiation Model of Care: BIC-NOW Clinical Trial (BIC-NOW)

• Status: Completed
• Trial end date: 2023-10-30
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to analyze in treatment-naïve HIV patients the antiviral activity, using a test and treat strategy, in real life of BIC/FTC/TAF. Secondary, this study aims to evaluate outcomes for implementation of the evidence based test and treat strategy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Carmen Hidalgo Tenorio
• Collaborator: Gilead Sciences

Criteria

Inclusion Criteria:

1. HIV-1 infected adults (>17 y.o.)

2. Antiretroviral-naïve.

3. Be able to comply with protocol requirements and instructions.

4. Subject or the subject's representative capable of giving signed informed consent

Exclusion Criteria:

1. Women who are breastfeeding or plan to become pregnant during the study.

2. Patients who in the investigator's judgment, poses a significant drop out risk or life expectancy inferior to study ending.

3. Patients with anticipated need to change the ART before study ending.